Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moolec ScienceMLEC -2.94%42 Cash-to-Debt is 0.02 as of Dec. 2025, which is 91% below its 10-year median of 0.22. GuruFocus rates MLEC with a GF Score™ of 42/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,398 Biotechnology companies, Moolec Science ranks worse than 98.43% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Moolec Science's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Moolec Sciencecouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Moolec Science's Cash-to-Debt or its related term are showing as below:
MLEC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.22 Max: No Debt
Current: 0.02
During the past 5 years, Moolec Science's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.22.
MLEC's Cash-to-Debt is ranked worse than 98.43% of 1398
companies
in the Biotechnology industry
Industry Median: 6.68
vs MLEC: 0.02
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Moolec Science Cash-to-Debt Related Terms
Moolec Science Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Moolec Science's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Moolec Science's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Moolec Science's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a Cash-to-Debt of 0.02 as of Dec. 2025. This is 91% below median its historical median of 0.22. Over the past decade, Moolec Science's Cash-to-Debt has ranged from 0.02 to 10,000.00. According to the industry distribution chart, Moolec Science ranks #1376 out of 1398 companies in the Biotechnology industry, placing it in the top 98.4%.
Is Moolec Science's Cash-to-Debt too high?
Moolec Science's current Cash-to-Debt of 0.02 is 91% below median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.68. Moolec Science's value of 0.02 is 99.7% below this industry median. Based on the distribution chart, Moolec Science ranks #1376 out of 1398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Cash-to-Debt compare to BRTX and ERNA?
According to the Biotechnology industry distribution chart, Moolec Science ranks #1376 out of 1398 companies for Cash-to-Debt. This places Moolec Science in the lower half of its industry. The industry median Cash-to-Debt is 6.68. Moolec Science's value of 0.02 is 99.7% below this benchmark. Historically, Moolec Science's own Cash-to-Debt has ranged from 0.02 to 10,000.00 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 6.68, Moolec Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.68, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moolec Science's current Cash-to-Debt of 0.02 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current Cash-to-Debt is 0.02, which is 91% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $6.93 — trading 91.8% below its estimated fair value. The current Cash-to-Debt is 0.02, which is 91% below median its 10-year median of 0.22 and 99.7% below the Biotechnology industry median of 6.68. Moolec Science's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Moolec Science (MLEC), the current Cash-to-Debt is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $6.93 is trading 91.8% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
Cash-to-Debt: 0.02 (91% below median its 10-year median of 0.22)
GF Value™: $84.84 vs. price of $6.93 (91.8% below fair value)
Industry Position: 99.7% below the Biotechnology median (#1376 of 1398)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
42GF Score
Get the complete analysis for MLEC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
